Their findings demonstrated that TP-0903 exhibited ex vivo activity in primary AML cells characterized by recurrent mutations like MLL-PTD, ASXL1, SRSF2, and WT1, which are known to be associated with unfavorable prognosis or to contribute to clinical resistance against AML-directed therapies. This evidence concerns the gene SRSF2 and acute myeloid leukemia.